Unveiling the veil of adipokines: A meta -analysis and systematic review in amyotrophic lateral sclerosis

Hamid Abbasi,Neda Jourabchi-ghadim,Ali Asgarzade,Mobin Mirshekari,Mehrangiz Ebrahimi-Mameghani

DOI: https://doi.org/10.1016/j.neuroscience.2024.11.003

2024-11-06

Neurosciences

Abstract:Highlights • Clinical evidence indicates the key role of adipokines in amyotrophic lateral sclerosis (ALS) pathophysiology. • This study is the first meta -analysis and systematic review of case-control studies published comparing the serum levels of adipokines in ALS patients compared with control groups. • Although serum adiponectin levels were elevated in ALS patients, the association was not statistically significant, though a trend was noted in older individuals. • ALS patients exhibited significantly lower serum leptin levels compared to controls, indicating a potential role of leptin deficiency in ALS progression. • These findings suggest that targeting adipokine signaling pathways, especially leptin and ghrelin, could present new therapeutic possibilities for ALS patients. Background Adipokines are proposed to be associated with ALS progression through assorted pathways. Therefore, The present meta -analysis explored the link between various adipokines and ALS progression. Method International database like PubMed, Scopus, and Web of Science databases were searched to achieve eligible papers published before December 2023. The following PICO structure was utilized: Population (patients with ALS); Intervention (serum concentrations of ghrelin, leptin, and adiponectin), Comparison (with or without controls), and Outcome (ALS progression). the risk of bias of selected papers was assessed through the Newcastle-Ottawa Scale (NOS) tool. Results 11 out of 240 papers were selected for this study which were published between 2010 and 2024. Lower serum leptin concentrations were detected in the ALS compared to control groups (WMD: −0.91, 95% CI:-1.77, −0.05). Serum concentrations of adiponectin were higher in ALS compared to control groups (WMD: 0.41, 95% CI:-0.7, 0.89). Ultimately, The serum concentrations of ghrelin in the ALS groups were lower than control groups (WMD: −1.21, 95% CI: −2.95, 0.53). Conclusion Our findings revealed that serum concentrations of ghrelin and leptin were higher in ALS patients compared to control, unlike adiponectin.

clinical neurology